Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 2,334 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PET (Positron Emission Tomography) Clear all

Conditions: Glioblastoma
Interventions: Radiologic exams; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Clear Cell Renal Cell Carcinoma (ccRCC), ccRCC
Interventions: 89Zr-Girentuximab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atherosclerosis
Interventions: Cu[64]-25%CANF-Comb; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Coronary Artery Disease
Interventions: Apadenoson SPECT-MPI, Adenosine SPECT-MPI; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 863 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 103
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 87 more

Conditions: Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Brachytherapy, Computed Tomography, Dual X-ray Absorptiometry, External Beam Radiation Therapy, Magnetic Resonance Imaging, PSMA PET Scan, Questionnaire Administration, Relugolix; Procedure · Radiation · Other + 1 more
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Metastatic Prostate Cancer, Prostate Cancer
Interventions: 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, FTT-PET/CT, EnhanceAR-Seq; Drug · Device · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Cervical Undifferentiated Carcinoma, Recurrent Cervical Carcinoma, Stage IB2 Cervical Cancer, Stage II Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer
Interventions: Computed Tomography, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Magnetic Resonance Spectroscopic Imaging, Positron Emission Tomography; Procedure · Radiation
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 4
States / cities: Miami, Florida • Maywood, Illinois • Columbus, Ohio + 1 more

Conditions: Alzheimer's Disease, Brain Neoplasm, Niemann Pick Disease
Interventions: 15 O Water; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Subject, Intracranial Neoplasm, Glioblastoma
Interventions: Fluorine F 18 DASA-23, Positron Emission Tomography; Drug · Procedure
Lead sponsor: Guido A. Davidzon, MD, SM; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Stable Coronary Disease
Interventions: Evolocumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Prostate Cancer
Interventions: [89Zr]Df-IAB2M; Biological
Lead sponsor: ImaginAb, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: 18F-rhPSMA-7.3; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Interstitial Lung Disease, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis, Hypersensitivity Pneumonitis, Radiation Pneumonitis, Pneumoconiosis, Pulmonary Fibrosis
Interventions: 68Ga-FAPi-46, Computed Tomography, Positron Emission Tomography, High Resolution Computed Tomography; Drug · Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bladder Cancer, Urothelial Carcinoma
Interventions: 18F-fluciclovine, PET/CT; Drug · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: [89Zr]-Df-Trastuzumab, PET/MRI Imaging; Drug · Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Central Nervous System Lymphoma
Interventions: Aspiration, Biospecimen Collection, Catheterization, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostate Cancer, Localized Prostate Cancer
Interventions: [18F] DIHYDRO-TESTOSTERONE, PET scan, MRI, Blood draw; Drug · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 79 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Cervical Cancer, Uterine Cancer
Interventions: 18F fluciclovine, 18F fluciclovine PET; Drug · Device
Lead sponsor: Nghi Nguyen; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glioblastoma Multiforme, Brain Metastases
Interventions: NM404; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: METASTATIC BREAST CANCER
Interventions: Positron emission tomography (PET/CT) imaging, radiotracer [18F]ISO-1; Device
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: [18F]MNI-968; Drug
Lead sponsor: Molecular NeuroImaging; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neurodegenerative Disease
Interventions: 18F-AV-1451; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: PET Scan, FLT, FDG; Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Esophagogastroduodenoscopy, Fluorouracil, Hypofractionated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Positron Emission Tomography, Survey Administration, Docetaxel, Durvalumab; Procedure · Drug · Radiation + 2 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Search by objective public record fields.

Evaluating Tumor Pseudoprogression With FLT-PET and MRI

CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer

PET Scan of Brain Metabolism in Relation to Age and Disease

[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk

Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

FAPI PET for Lung Fibrosis

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma

[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer

Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.

PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404

Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer

Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects

PET Tau - Neurodegenerative Disease Imaging

Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma